{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CBD", "Cannabidiol", "Cannabinoids", "Cannabis", "Marijuana", "Medicinal plants", "Mental health", "Pharmacogenomics", "THC"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31948424", "DateCompleted": {"Year": "2020", "Month": "12", "Day": "21"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "16"}], "Language": ["eng"], "ELocationID": ["24", "10.1186/s12888-019-2409-8"], "Journal": {"ISSN": "1471-244X", "JournalIssue": {"Volume": "20", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "16"}}, "Title": "BMC psychiatry", "ISOAbbreviation": "BMC Psychiatry"}, "ArticleTitle": "Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.", "Pagination": {"StartPage": "24", "MedlinePgn": "24"}, "Abstract": {"AbstractText": ["Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.", "The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived cannabinoid isolates in mood, anxiety, sleep, psychotic disorders and attention deficit/hyperactivity disorder (ADHD) is discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational and public health elements, and future research recommendations. The systematic review of the literature was conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted).", "The present evidence in the emerging field of cannabinoid therapeutics in psychiatry is nascent, and thereby it is currently premature to recommend cannabinoid-based interventions. Isolated positive studies have, however, revealed tentative support for cannabinoids (namely cannabidiol; CBD) for reducing social anxiety; with mixed (mainly positive) evidence for adjunctive use in schizophrenia. Case studies suggest that medicinal cannabis may be beneficial for improving sleep and post-traumatic stress disorder, however evidence is currently weak. Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC) therapeutics, or for CBD in mania. One isolated study indicates some potential efficacy for an oral cannabinoid/terpene combination in ADHD. Clinical prescriptive consideration involves caution in the use of high-THC formulations (avoidance in youth, and in people with anxiety or psychotic disorders), gradual titration, regular assessment, and caution in cardiovascular and respiratory disorders, pregnancy and breast-feeding.", "There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NICM Health Research Institute, Western Sydney University, Westmead, NSW, 2145, Australia. j.sarris@westernsydney.edu.au."}, {"Identifier": [], "Affiliation": "Department of Psychiatry, The Melbourne Clinic, Professorial Unit, The University of Melbourne, Melbourne, Australia. j.sarris@westernsydney.edu.au."}], "LastName": "Sarris", "ForeName": "Jerome", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NICM Health Research Institute, Western Sydney University, Westmead, NSW, 2145, Australia."}], "LastName": "Sinclair", "ForeName": "Justin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NICM Health Research Institute, Western Sydney University, Westmead, NSW, 2145, Australia."}], "LastName": "Karamacoska", "ForeName": "Diana", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NICM Health Research Institute, Western Sydney University, Westmead, NSW, 2145, Australia."}], "LastName": "Davidson", "ForeName": "Maggie", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NICM Health Research Institute, Western Sydney University, Westmead, NSW, 2145, Australia."}, {"Identifier": [], "Affiliation": "Division of Psychology and Mental Health, University of Manchester, Manchester, UK."}], "LastName": "Firth", "ForeName": "Joseph", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Systematic Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Psychiatry", "NlmUniqueID": "100968559", "ISSNLinking": "1471-244X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Medical Marijuana"}, {"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Anxiety"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cannabidiol"}, {"QualifierName": [], "DescriptorName": "Cannabinoids"}, {"QualifierName": [], "DescriptorName": "Cannabis"}, {"QualifierName": [], "DescriptorName": "Child"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Medical Marijuana"}], "CoiStatement": "<b>JS1</b> and <b>JS2</b> conduct cannabis research as university\u00a0members of the Australia Medicinal Cannabis Research and Education Collaboration (www.AMCREC.org). <b>JS1</b> has received consultancy payment from a cannabis manufacturing company as an independent scientific advisor (Australian Natural Therapeutics Group); this was however received many\u00a0months after the creation and\u00a0submission of this publication and was unrelated to this manuscript. He has also received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Research Reviews, Taki Mai, Fiji Kava,\u00a0Bioceuticals & Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, Society for Medicinal Plant and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National Health and Medical Research Council, CR Roper Fellowship. <b>JS2</b> has sat on the Scientific Advisory Board for BioCeuticals."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Merlin M. Archaeological evidence for the tradition of psychoactive plant use in the old world. Econ Bot. 2003;57:295\u2013323. doi: 10.1663/0013-0001(2003)057[0295:AEFTTO]2.0.CO;2.", "ArticleIdList": ["10.1663/0013-0001(2003)057[0295:AEFTTO]2.0.CO;2"]}, {"Citation": "National Academies of Sciences E, Medicine . The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.", "ArticleIdList": ["28182367"]}, {"Citation": "Touwn M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13:23\u201334. doi: 10.1080/02791072.1981.10471447.", "ArticleIdList": ["10.1080/02791072.1981.10471447", "7024492"]}, {"Citation": "Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153\u2013157. doi: 10.1590/S1516-44462006000200015.", "ArticleIdList": ["10.1590/S1516-44462006000200015", "16810401"]}, {"Citation": "Russo E. The pharmacological history of Cannabis. In: Pertwee R, editor. Handbook of cannabis. Oxford: Oxford University Press; 2016. pp. 23\u201343."}, {"Citation": "Thompson R. A dictionary of Assyrian botany. British Academy: London; 1949."}, {"Citation": "Grierson G. The hemp plant in Sanskrit and hindi literature. Indian Antiqu. 1894;September:260\u2013262."}, {"Citation": "Da Orta G. Colloquies on the simples and drugs of India. London: Henry Sotheran; 1913."}, {"Citation": "Kosiba JD, Maisto SA, Joseph W. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;", "ArticleIdList": ["31207470"]}, {"Citation": "Whiting Penny F., Wolff Robert F., Deshpande Sohan, Di Nisio Marcello, Duffy Steven, Hernandez Adrian V., Keurentjes J. Christiaan, Lang Shona, Misso Kate, Ryder Steve, Schmidlkofer Simone, Westwood Marie, Kleijnen Jos. Cannabinoids for Medical Use. JAMA. 2015;313(24):2456. doi: 10.1001/jama.2015.6358.", "ArticleIdList": ["10.1001/jama.2015.6358", "26103030"]}, {"Citation": "Drysdale AJ, Platt B. Cannabinoids: mechanisms and therapeutic applications in the CNS. (0929\u20138673 (Print)).", "ArticleIdList": ["14529462"]}, {"Citation": "The National Institutes of Health. Marijuana and cannabinoids: a neuroscience research summit. Bethesda; 2016."}, {"Citation": "Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017;121:213\u2013218. doi: 10.1016/j.phrs.2017.05.005.", "ArticleIdList": ["10.1016/j.phrs.2017.05.005", "28501518"]}, {"Citation": "Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56(23\u201324):2097\u20132102. doi: 10.1016/0024-3205(95)00194-B.", "ArticleIdList": ["10.1016/0024-3205(95)00194-B", "7776837"]}, {"Citation": "ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017;103:1\u201336.", "ArticleIdList": ["28120229"]}, {"Citation": "Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344\u20131364. doi: 10.1111/j.1476-5381.2011.01238.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01238.x", "PMC3165946", "21749363"]}, {"Citation": "Hanus LO, Meyer SM, Munoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357\u20131392. doi: 10.1039/C6NP00074F.", "ArticleIdList": ["10.1039/C6NP00074F", "27722705"]}, {"Citation": "Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, Garcia-Taboada E, et al. Appraising the \u201centourage effect\u201d: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018;", "ArticleIdList": ["29940172"]}, {"Citation": "Khoury JM, Neves M, Roque MAV, Queiroz DAB, Correa de Freitas AA, de Fatima A, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry. 2017:1\u201316.", "ArticleIdList": ["28112021"]}, {"Citation": "Habib G, Artul S. Medical cannabis for the treatment of fibromyalgia. J Clin Rheumatol. 2018;14:14.", "ArticleIdList": ["29461346"]}, {"Citation": "Miller RJ, Miller RE. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 2017;35 Suppl 107(5):59\u201367. doi: 10.1007/s10067-016-3468-6.", "ArticleIdList": ["10.1007/s10067-016-3468-6", "28967368"]}, {"Citation": "Kim PS, Fishman MA. Cannabis for pain and headaches: primer. Curr Pain Headache Rep. 2017;21(4):19. doi: 10.1007/s11916-017-0619-7.", "ArticleIdList": ["10.1007/s11916-017-0619-7", "28281107"]}, {"Citation": "Reddy DS. The utility of cannabidiol in the treatment of refractory epilepsy. Clin Pharmacol Ther. 2017;101(2):182\u2013184. doi: 10.1002/cpt.441.", "ArticleIdList": ["10.1002/cpt.441", "27506704"]}, {"Citation": "O\u2019Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav E&B. 2017;70(Pt B):341\u2013348. doi: 10.1016/j.yebeh.2016.11.012.", "ArticleIdList": ["10.1016/j.yebeh.2016.11.012", "28188044"]}, {"Citation": "Landa L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;19:19.", "ArticleIdList": ["29560966"]}, {"Citation": "Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ. Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16) Med J Aust. 2018;209(5):211\u2013216. doi: 10.5694/mja17.01247.", "ArticleIdList": ["10.5694/mja17.01247", "30092752"]}, {"Citation": "Lisboa SF, Gomes FV, Terzian AL, Aguiar DC, Moreira FA, Resstel LB, et al. The endocannabinoid system and anxiety. Vitam Horm. 2017;103:193\u2013279. doi: 10.1016/bs.vh.2016.09.006.", "ArticleIdList": ["10.1016/bs.vh.2016.09.006", "28061971"]}, {"Citation": "Ruehle S, Rey AA, Remmers F, Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol (Oxford, UK) 2012;26(1):23\u201339. doi: 10.1177/0269881111408958.", "ArticleIdList": ["10.1177/0269881111408958", "PMC3267552", "21768162"]}, {"Citation": "Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037\u20131043. doi: 10.1007/s11064-005-6978-1.", "ArticleIdList": ["10.1007/s11064-005-6978-1", "16258853"]}, {"Citation": "Howlett AC, Blume LC, Dalton GD. CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem. 2010;17(14):1382\u20131393. doi: 10.2174/092986710790980023.", "ArticleIdList": ["10.2174/092986710790980023", "PMC3179980", "20166926"]}, {"Citation": "Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199\u2013215. doi: 10.1038/sj.bjp.0707442.", "ArticleIdList": ["10.1038/sj.bjp.0707442", "PMC2219532", "17828291"]}, {"Citation": "Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764\u2013774. doi: 10.1038/npp.2009.184.", "ArticleIdList": ["10.1038/npp.2009.184", "PMC3055598", "19924114"]}, {"Citation": "Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther. 1976;19(3):300\u2013309. doi: 10.1002/cpt1976193300.", "ArticleIdList": ["10.1002/cpt1976193300", "770048"]}, {"Citation": "Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19\u201327. doi: 10.1177/0269881112460109.", "ArticleIdList": ["10.1177/0269881112460109", "23042808"]}, {"Citation": "Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 \u2013 tetrahydrocannabinol in man. Eur J Pharmacol. 1974;28(1):172\u2013177. doi: 10.1016/0014-2999(74)90129-0.", "ArticleIdList": ["10.1016/0014-2999(74)90129-0", "4609777"]}, {"Citation": "Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. doi: 10.1186/1471-244X-14-136.", "ArticleIdList": ["10.1186/1471-244X-14-136", "PMC4032500", "24884989"]}, {"Citation": "Feingold D, Rehm J, Factor H, Redler A, Lev-Ran S. Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: a 3-year population-based longitudinal study. Depress Anxiety. 2018;35(6):490\u2013501. doi: 10.1002/da.22735.", "ArticleIdList": ["10.1002/da.22735", "29486095"]}, {"Citation": "Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u20131226. doi: 10.1038/npp.2011.6.", "ArticleIdList": ["10.1038/npp.2011.6", "PMC3079847", "21307846"]}, {"Citation": "Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (Oxford, UK) 2011;25(1):121\u2013130. doi: 10.1177/0269881110379283.", "ArticleIdList": ["10.1177/0269881110379283", "20829306"]}, {"Citation": "Buckner JD, Heimberg RG, Ecker AH, Vinci C. A biopsychosocial model of social anxiety and substance use. Depress Anxiety. 2013;30(3):276\u2013284. doi: 10.1002/da.22032.", "ArticleIdList": ["10.1002/da.22032", "23239365"]}, {"Citation": "Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825\u2013836. doi: 10.1007/s13311-015-0387-1.", "ArticleIdList": ["10.1007/s13311-015-0387-1", "PMC4604171", "26341731"]}, {"Citation": "Hitchcock L. 2018. Available from https://clinicaltrials.gov/ct2/show/NCT03491384?cond=Anxiety&intr=Cannabis&rank=2."}, {"Citation": "ACTRN12617000825358. The cannabidiol youth anxiety pilot study (CAPS): a 12-week open- label pilot study of the safety, tolerability and efficacy of cannabidiol for anxiety disorders."}, {"Citation": "Yarnell S. The use of medicinal marijuana for posttraumatic stress disorder: a review of the current literature. Prim Care Companion CNS Disord. 2015;17(3)", "ArticleIdList": ["PMC4578915", "26644963"]}, {"Citation": "Betthauser K, Pilz J, Vollmer LE. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health-Syst Pharm. 2015;72(15):1279\u20131284. doi: 10.2146/ajhp140523.", "ArticleIdList": ["10.2146/ajhp140523", "26195653"]}, {"Citation": "Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299\u2013318. doi: 10.1016/S0306-4522(96)00428-9.", "ArticleIdList": ["10.1016/S0306-4522(96)00428-9", "9472392"]}, {"Citation": "Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology. 2008;33(1):56\u201372. doi: 10.1038/sj.npp.1301555.", "ArticleIdList": ["10.1038/sj.npp.1301555", "PMC2668714", "17882236"]}, {"Citation": "Papini S, Sullivan GM, Hien DA, Shvil E, Neria Y. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research. Biol Psychol. 2015;104:8\u201318. doi: 10.1016/j.biopsycho.2014.10.010.", "ArticleIdList": ["10.1016/j.biopsycho.2014.10.010", "PMC4465924", "25448242"]}, {"Citation": "Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530\u2013534. doi: 10.1038/nature00839.", "ArticleIdList": ["10.1038/nature00839", "12152079"]}, {"Citation": "Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem. 2004;11(5):625\u2013632. doi: 10.1101/lm.77904.", "ArticleIdList": ["10.1101/lm.77904", "PMC523082", "15466318"]}, {"Citation": "Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162\u2013165. doi: 10.1016/j.drugalcdep.2013.12.008.", "ArticleIdList": ["10.1016/j.drugalcdep.2013.12.008", "PMC3929256", "24412475"]}, {"Citation": "Johnson MJ, Pierce JD, Mavandadi S, Klaus J, Defelice D, Ingram E, et al. Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD. J Affect Disord. 2016;190:439\u2013442. doi: 10.1016/j.jad.2015.10.048.", "ArticleIdList": ["10.1016/j.jad.2015.10.048", "26551402"]}, {"Citation": "Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25(4):392\u2013397. doi: 10.1089/acm.2018.0437.", "ArticleIdList": ["10.1089/acm.2018.0437", "PMC6482919", "30543451"]}, {"Citation": "Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical cannabis Program. J Psychoactive Drugs. 2014;46(1):73\u201377. doi: 10.1080/02791072.2013.873843.", "ArticleIdList": ["10.1080/02791072.2013.873843", "24830188"]}, {"Citation": "NCT02517424. Placebo-Controlled, Triple-Blind, Crossover study of the safety and efficacy of three different potencies of vaporized Cannabis in 42 participants with chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)."}, {"Citation": "NCT02759185. Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With Posttraumatic Stress Disorder (PTSD)."}, {"Citation": "Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281\u2013291. doi: 10.1001/jamapsychiatry.2013.3947.", "ArticleIdList": ["10.1001/jamapsychiatry.2013.3947", "24430917"]}, {"Citation": "Podda G, Constantinescu CS. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opin Biol Ther. 2012;12(11):1517\u20131531. doi: 10.1517/14712598.2012.721765.", "ArticleIdList": ["10.1517/14712598.2012.721765", "22954177"]}, {"Citation": "Trigo Jose M., Soliman Alexandra, Quilty Lena C., Fischer Benedikt, Rehm J\u00fcrgen, Selby Peter, Barnes Allan J., Huestis Marilyn A., George Tony P., Streiner David L., Staios Gregory, Le Foll Bernard. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLOS ONE. 2018;13(1):e0190768. doi: 10.1371/journal.pone.0190768.", "ArticleIdList": ["10.1371/journal.pone.0190768", "PMC5791962", "29385147"]}, {"Citation": "Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438\u2013449. doi: 10.1016/j.jpain.2012.01.003.", "ArticleIdList": ["10.1016/j.jpain.2012.01.003", "22483680"]}, {"Citation": "Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797\u2013810. doi: 10.1017/S0033291713001438.", "ArticleIdList": ["10.1017/S0033291713001438", "23795762"]}, {"Citation": "Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. (2378\u20138763 (Print)).", "ArticleIdList": ["PMC5549439", "28861489"]}, {"Citation": "Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729\u20131743. doi: 10.1002/cbdv.200790150.", "ArticleIdList": ["10.1002/cbdv.200790150", "17712817"]}, {"Citation": "Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE. Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. Front Pharmacol. 2016;7", "ArticleIdList": ["PMC5062916", "27790138"]}, {"Citation": "Webb CW, Webb SM. Therapeutic benefits of cannabis: a patient survey. Hawai\u2019i J Med Public Health. 2014;73(4):109\u2013111.", "ArticleIdList": ["PMC3998228", "24765558"]}, {"Citation": "Ostadhadi S, Rahmatollahi M, Dehpour AR, Rahimian R. Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review. Phytother Res PTR. 2015;29(3):332\u2013338. doi: 10.1002/ptr.5265.", "ArticleIdList": ["10.1002/ptr.5265", "25504799"]}, {"Citation": "Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder\u2013related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559\u2013564. doi: 10.1097/JCP.0000000000000180.", "ArticleIdList": ["10.1097/JCP.0000000000000180", "PMC4165471", "24987795"]}, {"Citation": "Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43(2):128\u2013135. doi: 10.1080/02791072.2011.587700.", "ArticleIdList": ["10.1080/02791072.2011.587700", "21858958"]}, {"Citation": "Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20(4):108\u2013111.", "ArticleIdList": ["PMC5101100", "27768570"]}, {"Citation": "Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18\u2013041.", "ArticleIdList": ["PMC6326553", "30624194"]}, {"Citation": "Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46(2):207\u2013218. doi: 10.1016/j.jpainsymman.2012.07.014.", "ArticleIdList": ["10.1016/j.jpainsymman.2012.07.014", "23141881"]}, {"Citation": "ACTRN12618000078257. A study to evaluate the efficacy of sublingual cannabinoid based medicine extract compared with placebo for the treatment of Insomnia."}, {"Citation": "D\u2019Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):413\u2013431. doi: 10.1007/s00406-009-0024-2.", "ArticleIdList": ["10.1007/s00406-009-0024-2", "PMC2864503", "19609589"]}, {"Citation": "Manseau MW, Goff DC. Cannabinoids and schizophrenia: risks and therapeutic potential. Neurotherapeutics. 2015;12(4):816\u2013824. doi: 10.1007/s13311-015-0382-6.", "ArticleIdList": ["10.1007/s13311-015-0382-6", "PMC4604190", "26311150"]}, {"Citation": "Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319\u2013328. doi: 10.1016/S0140-6736(07)61162-3.", "ArticleIdList": ["10.1016/S0140-6736(07)61162-3", "17662880"]}, {"Citation": "Carney R, Cotter J, Firth J, Bradshaw T, Yung AR. Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr Scand. 2017;136(1):5\u201315. doi: 10.1111/acps.12699.", "ArticleIdList": ["10.1111/acps.12699", "PMC5484316", "28168698"]}, {"Citation": "Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549\u2013556. doi: 10.1016/j.biopsych.2015.08.001.", "ArticleIdList": ["10.1016/j.biopsych.2015.08.001", "26386480"]}, {"Citation": "van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol. 2014;10:767\u2013791. doi: 10.1146/annurev-clinpsy-032813-153631.", "ArticleIdList": ["10.1146/annurev-clinpsy-032813-153631", "24471373"]}, {"Citation": "Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193(5):357\u2013363. doi: 10.1192/bjp.bp.107.046375.", "ArticleIdList": ["10.1192/bjp.bp.107.046375", "18978312"]}, {"Citation": "Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 2016;46(4):673\u2013681. doi: 10.1017/S0033291715002329.", "ArticleIdList": ["10.1017/S0033291715002329", "26568030"]}, {"Citation": "Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u2013436. doi: 10.1016/S2215-0366(19)30048-3.", "ArticleIdList": ["10.1016/S2215-0366(19)30048-3", "PMC7646282", "30902669"]}, {"Citation": "Gage SHJTLP. Cannabis and psychosis: triangulating the evidence. 2019;6(5):364\u20135.", "ArticleIdList": ["30902668"]}, {"Citation": "Sommer IE, van den Brink WIM. High-potency cannabis and incident psychosis: correcting the causal assumption. 2019;6(6):464\u20135.", "ArticleIdList": ["31122471"]}, {"Citation": "Linnman CJTLP. High-potency cannabis and incident psychosis: correcting the causal assumption. 2019;6(6):465\u20136.", "ArticleIdList": ["31122473"]}, {"Citation": "Clark CSJTLP. High-potency cannabis and incident psychosis: correcting the causal assumption. 2019;6(6):e14.", "ArticleIdList": ["31122483"]}, {"Citation": "Gillespie Nathan A, Pasman Joelle A, Treur Jorien L, Derks Eske M, Verweij Karin J H, Vink Jacqueline M. High-potency cannabis and incident psychosis: correcting the causal assumption. The Lancet Psychiatry. 2019;6(6):464. doi: 10.1016/S2215-0366(19)30174-9.", "ArticleIdList": ["10.1016/S2215-0366(19)30174-9", "31122472"]}, {"Citation": "Di Forti M, Morgan C, Selten JP, Lynskey M, Murray RM. High-potency cannabis and incident psychosis: correcting the causal assumption \u2013 Authors\u2019 reply. Lancet Psychiatry. 2019;6(6):466\u2013467. doi: 10.1016/S2215-0366(19)30176-2.", "ArticleIdList": ["10.1016/S2215-0366(19)30176-2", "31122474"]}, {"Citation": "Weiser M, Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci. 2005;7(1):81\u201385.", "ArticleIdList": ["PMC3181719", "16060598"]}, {"Citation": "Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, et al. Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull. 2015;41(5):1171\u20131182. doi: 10.1093/schbul/sbv032.", "ArticleIdList": ["10.1093/schbul/sbv032", "PMC4535639", "25829376"]}, {"Citation": "Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195(6):488\u2013491. doi: 10.1192/bjp.bp.109.064220.", "ArticleIdList": ["10.1192/bjp.bp.109.064220", "PMC2801827", "19949195"]}, {"Citation": "Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull. 2008;34(6):1111\u20131121. doi: 10.1093/schbul/sbn108.", "ArticleIdList": ["10.1093/schbul/sbn108", "PMC2632498", "18723841"]}, {"Citation": "Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262\u20131269. doi: 10.1093/schbul/sbw003.", "ArticleIdList": ["10.1093/schbul/sbw003", "PMC4988731", "26884547"]}, {"Citation": "Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, et al. \u03949-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002;948(1):155\u2013158. doi: 10.1016/S0006-8993(02)03055-X.", "ArticleIdList": ["10.1016/S0006-8993(02)03055-X", "12383968"]}, {"Citation": "Colizzi M, Weltens N, McGuire P, Lythgoe D, Williams S, Van Oudenhove L, et al. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. 2019;", "ArticleIdList": ["PMC7714685", "30770892"]}, {"Citation": "D\u2019Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558\u20131572. doi: 10.1038/sj.npp.1300496.", "ArticleIdList": ["10.1038/sj.npp.1300496", "15173844"]}, {"Citation": "D\u2019Souza DC, Abi-Saab Wm Fau \u2013 Madonick S, Madonick S Fau \u2013 Forselius-Bielen K, Forselius-Bielen K Fau \u2013 Doersch A, Doersch A Fau \u2013 Braley G, Braley G Fau \u2013 Gueorguieva R, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. (0006\u20133223 (Print)).", "ArticleIdList": ["15780846"]}, {"Citation": "Rohleder C, M\u00fcller JK, Lange B, Leweke FM. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol. 2016;7", "ArticleIdList": ["PMC5099166", "27877130"]}, {"Citation": "Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry. 2016;79(7):604\u2013612. doi: 10.1016/j.biopsych.2015.11.018.", "ArticleIdList": ["10.1016/j.biopsych.2015.11.018", "26852073"]}, {"Citation": "Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94. doi: 10.1038/tp.2012.15.", "ArticleIdList": ["10.1038/tp.2012.15", "PMC3316151", "22832859"]}, {"Citation": "Zuardi AW, Morais SL, Guimar\u00e3es FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485\u2013486.", "ArticleIdList": ["7559378"]}, {"Citation": "McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u2013231. doi: 10.1176/appi.ajp.2017.17030325.", "ArticleIdList": ["10.1176/appi.ajp.2017.17030325", "29241357"]}, {"Citation": "Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. 2018;", "ArticleIdList": ["29619533"]}, {"Citation": "Bhattacharyya S, Wilson R, Appiah-Kusi E, O\u2019Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry. 2018;", "ArticleIdList": ["PMC6248101", "30167644"]}, {"Citation": "ISRCTN10334895. Cannabidiol for the treatment of patients at a high-risk of psychosis."}, {"Citation": "Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24:135\u2013137. doi: 10.1177/0269881108096521.", "ArticleIdList": ["10.1177/0269881108096521", "18801823"]}, {"Citation": "Mitchell JT, Sweitzer MM, Tunno AM, Kollins SH, McClernon FJ. \u201cI use weed for my ADHD\u201d: a qualitative analysis of online forum discussions on cannabis use and ADHD. PloS one. 2016;11(5):e0156614. doi: 10.1371/journal.pone.0156614.", "ArticleIdList": ["10.1371/journal.pone.0156614", "PMC4882033", "27227537"]}, {"Citation": "Marijuana and Medicine: The Need for a Science-Based Approach: Hearing before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, U.S. House of Representatives, Second Sess. (April 1, 2004)."}, {"Citation": "Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795\u2013808. doi: 10.1016/j.euroneuro.2017.05.005.", "ArticleIdList": ["10.1016/j.euroneuro.2017.05.005", "28576350"]}, {"Citation": "Beaulieu P, Boulanger A, Desroches J, Clark AJ. Medical cannabis: considerations for the anesthesiologist and pain physician. Canadian journal of anaesthesia = J Can d\u2019anesthesie. 2016;63(5):608\u2013624. doi: 10.1007/s12630-016-0598-x.", "ArticleIdList": ["10.1007/s12630-016-0598-x", "26850063"]}, {"Citation": "HelloMD . Medical marijuana: patient survey results. 2016."}, {"Citation": "Millar S, Stone N, Bellman Z, Yates A, England T, O\u2019Sullivan S. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019;", "ArticleIdList": ["PMC6710502", "31222854"]}, {"Citation": "MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u201319. doi: 10.1016/j.ejim.2018.01.004.", "ArticleIdList": ["10.1016/j.ejim.2018.01.004", "29307505"]}, {"Citation": "Kamal BS, Kamal F, Lantela DE. Cannabis and the anxiety of fragmentation-a systems approach for finding an anxiolytic cannabis chemotype. Front Neurosci. 2018;12:730. doi: 10.3389/fnins.2018.00730.", "ArticleIdList": ["10.3389/fnins.2018.00730", "PMC6204402", "30405331"]}, {"Citation": "Hryhorowicz S, Walczak M, Zakerska-Banaszak O, Slomski R, Skrzypczak-Zielinska M. Pharmacogenetics of cannabinoids. Eur J Drug Metab Pharmacokinet. 2018;43(1):1\u201312. doi: 10.1007/s13318-017-0416-z.", "ArticleIdList": ["10.1007/s13318-017-0416-z", "PMC5794848", "28534260"]}, {"Citation": "Goldsmith RS, Hartenbaum NP, Martin DW. Medical marijuana in the workforce. J Occup Environ Med. 2015;57(11):e139. doi: 10.1097/JOM.0000000000000516.", "ArticleIdList": ["10.1097/JOM.0000000000000516", "26539777"]}, {"Citation": "Bowles NP, Herzig MX, Shea SA. Recent legalization of cannabis use: effects on sleep, health, and workplace safety. Nat Sci Sleep. 2017;9:249\u2013251. doi: 10.2147/NSS.S152231.", "ArticleIdList": ["10.2147/NSS.S152231", "PMC5656354", "29089789"]}, {"Citation": "Allen JG, Prichard J, Griggs L. A workplace drug testing act for Australia. Univ Qld Law J. 2013;32(2):219\u2013237."}, {"Citation": "Safe Work Australia. Drugs and alcohol canberra: safe work Australia. 2017. Available from https://www.safeworkaustralia.gov.au/drugs-alcohol."}, {"Citation": "WorkCover NSW . Alcohol and other drugs in the workplace: guide to developing a workplace alcohol and other drugs policy. Perth: WorkCover NSW; 2006."}, {"Citation": "Stringham C, Allard I, Knapp S, Minor M. Medical marijuana in the work place: keeping small business informed. Small Bus Inst J. 2017;13(1):16."}, {"Citation": "Goldsmith RS, Targino MC, Fanciullo GJ, Martin DW, Hartenbaum NP, White JM, et al. Medical marijuana in the workplace: challenges and management options for occupational physicians. J Occup Environ Med. 2015;57(5):518. doi: 10.1097/JOM.0000000000000454.", "ArticleIdList": ["10.1097/JOM.0000000000000454", "PMC4410963", "25951421"]}, {"Citation": "CCOHS . Safety CCfOHa. Ontario: Candian Centre for Occupational Health and Safety; 2018. Workplace strategies: risk of impairment from cannabis."}, {"Citation": "Phillips JA, Holland MG, Baldwin DD, Gifford-Meuleveld L, Mueller KL, Perkison B, et al. Marijuana in the workplace: guidance for occupational health professionals and employers: joint guidance statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. Workplace Health Saf. 2015;63(4):139\u2013164. doi: 10.1177/2165079915581983.", "ArticleIdList": ["10.1177/2165079915581983", "25862727"]}, {"Citation": "Casarett D. The achilles heel of medical cannabis research\u2014inadequate blinding of placebo-controlled trials. JAMA Intern Med. 2018;178(1):9\u201310. doi: 10.1001/jamainternmed.2017.5308.", "ArticleIdList": ["10.1001/jamainternmed.2017.5308", "29159413"]}]}], "History": [{"Year": "2019", "Month": "1", "Day": "22"}, {"Year": "2019", "Month": "12", "Day": "15"}, {"Year": "2020", "Month": "1", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["31948424", "PMC6966847", "10.1186/s12888-019-2409-8", "10.1186/s12888-019-2409-8"]}}]}